Pharmaceutical Company to Pay $625M for Allegedly Repackaging Cancer Meds
To make more money, the company allegedly “broke their sterility, pooled the contents, and repackaged the drugs into pre-filled syringes.”

Eric Gaillard/Reuters
Pharmaceutical company AmerisourceBergen Corporation will pay $625 million after it allegedly harvested “overfill” from FDA-approved sterile vials of cancer medication and repackaged the drugs in its own pre-filled syringes in non-sterile conditions, according to the Justice Department. The company, which sought to profit off of the excess product contained in the sterile drug vials, was accused of breaking the sterility of the vials by opening them and pooling them together for repackaging in syringes. It then sent “millions” of syringes out for distribution to “vulnerable” cancer patients, prosecutors allege. The Justice Department also claims the company gave doctors “kickbacks” to make them purchase the pre-filled syringes. The alleged scheme was brought to light by three whistleblowers in civil-action lawsuits. The whistleblowers will each receive $93,089,441. “ABC placed corporate profits over patients’ needs, endangering the health of vulnerable cancer patients,” said U.S. Attorney Richard Donoghue.
Register below to read this article for free or subscribe
to unlock unlimited access to The Daily Beast.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Already have an account? Sign In
Looks like you already have a subscription!
You're all set!
Thanks for subscribing.